Log in

NASDAQ:ARDM - Aradigm Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.15
0.00 (0.00 %)
(As of 01/26/2020 04:00 PM ET)
Today's Range
$0.15
Now: $0.15
$0.15
50-Day Range
$0.15
MA: $0.24
$0.38
52-Week Range
$0.07
Now: $0.15
$2.33
Volume2 shs
Average Volume97,091 shs
Market Capitalization$2.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.57
Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARDM
CUSIPN/A
Phone510-265-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.47 million
Book Value($0.83) per share

Profitability

Net Income$-10,700,000.00
Net Margins-374.80%

Miscellaneous

EmployeesN/A
Market Cap$2.28 million
Next Earnings DateN/A
OptionableOptionable

Receive ARDM News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDM and its competitors with MarketBeat's FREE daily newsletter.


Aradigm (NASDAQ:ARDM) Frequently Asked Questions

What is Aradigm's stock symbol?

Aradigm trades on the NASDAQ under the ticker symbol "ARDM."

How were Aradigm's earnings last quarter?

Aradigm Co. (NASDAQ:ARDM) posted its quarterly earnings data on Thursday, November, 15th. The company reported ($0.24) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.03. The firm had revenue of $0.28 million for the quarter. View Aradigm's Earnings History.

Has Aradigm been receiving favorable news coverage?

Media headlines about ARDM stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aradigm earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Aradigm.

Who are some of Aradigm's key competitors?

What other stocks do shareholders of Aradigm own?

Who are Aradigm's key executives?

Aradigm's management team includes the folowing people:
  • Dr. John M. Siebert, Exec. Chairman, Interim Principal Exec. Officer & Acting Principal Financial Officer (Age 79)
  • Dr. Juergen Froehlich M.D., MBA, FCPh, Chief Medical Officer (Age 62)
  • Dr. Igor Gonda, Consultant (Age 71)
  • Ms. Nancy E. Pecota, Consultant (Age 59)
  • Lisa Thomas, Corp. Controller

What is Aradigm's stock price today?

One share of ARDM stock can currently be purchased for approximately $0.15.

How big of a company is Aradigm?

Aradigm has a market capitalization of $2.28 million and generates $14.47 million in revenue each year. The company earns $-10,700,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. View Additional Information About Aradigm.

What is Aradigm's official website?

The official website for Aradigm is http://www.aradigm.com/.

How can I contact Aradigm?

Aradigm's mailing address is 3929 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-265-9000 or via email at [email protected]


MarketBeat Community Rating for Aradigm (NASDAQ ARDM)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  262 (Vote Underperform)
Total Votes:  447
MarketBeat's community ratings are surveys of what our community members think about Aradigm and other stocks. Vote "Outperform" if you believe ARDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/26/2020 by MarketBeat.com Staff

Featured Article: Do You Need a Fiduciary?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel